Not exact matches
As researchers learn more about
genetic profile of various cancers, other work is charging ahead to deliver personalized vaccines targeted to a patient's own
tumor cells
Traditional
genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be
profiled for their ability to selectively kill cells in a molecular context that matches those found in
tumors.
Most cancer patients would opt for
tumor profiling even if the test revealed that they or their families were at risk for other
genetic diseases, according to a Yale Cancer Center study.
The 15 AACR scientists, who were already in Washington, D.C., to meet with the U.S. Food and Drug Administration on
genetic testing for cancer patients, tossed around ideas including expanding NCI's
tumor genome - sequencing efforts and getting the government to cover the costs of genomic
tumor profiling.
Increasingly sophisticated
tumor profiling technology has led to advancements in diagnosing and treating
genetic diseases like cancer.
The resulting «map» of gene - drug interactions allowed the researchers to accurately predict the responses of multiple human cancer cell lines to different chemotherapy agents based on the cell lines»
genetic profiles and also revealed new
genetic factors that appear to determine the response of breast and ovarian
tumor cells to common classes of chemotherapy treatment.
This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular
profile of individual
tumors and the
genetic background of patients.
«The idea is that every patient will receive a unique cocktail of neoepitope - derived peptides, based on the
genetic profile of a
tumor, to generate a highly immunogenic and clinically relevant response,» he says.
The investigators also identified instances in which the
genetic profiles of metastases were similar to those of only some cells in the primary
tumor, suggesting that those cells were the source of the metastases, and other cases in which the
genetic profiles of metastases from the same primary differed depending on their location.
The total environmental DNA of grape crown gall
tumor disease is revealed in the
genetic profile based on 52 tissue samples of crown gall
tumor taken from 16 grapevine species.
Previously,
genetic counselors tested a small number of genes sequentially based on family
profile and
tumor analysis until the culprit was identified.
There's a basic set of mutational
profiling that's done all around the country but there are certain centers, including ours, that have access to a much wider set of
genetic profiling of the
tumors.
They envision using this technique to create mice with
tumors carrying the same
genetic profile as a patient, then testing different drugs on them to see which have the best effect.
Furthermore, the
genetic and expression
profiles of malignant cells vary within individual
tumors, between
tumors at different sites within the same patient, and among
tumors from different patients.
In the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the
genetic conditions predisposing to
tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her
genetic profile, in other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our
genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.»
A clinical trial of AI therapy response paired with next - gen sequencing offers the opportunity to
profile the
genetic alterations of AI - sensitive and AI - resistant
tumors.
Our groundbreaking Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing on the
genetic analysis of pediatric cancer patients including in children with malignant brain
tumors, and determines whether targeted treatments may be available based upon their personalized
tumor genomic sequencing
profiles.
To determine the
genetic profile of a patient's
tumor and identify cancer - driving genes, our team of experts uses advanced genomic sequencing technology.
In precision medicine, molecular
profiling of an individual patient's
tumor is used to identify
genetic mutations that drive that...